Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines

被引：70

作者：

Hoppe, Richard T. ^{[1
]}

Advani, Ranjana H. ^{[1
]}

Ai, Weiyun Z. ^{[2
]}

Ambinder, Richard F. ^{[3
]}

Aoun, Patricia ^{[4
]}

Bello, Celeste M. ^{[5
]}

Bierman, Philip J. ^{[4
]}

Blum, Kristie A. ^{[6
]}

Chen, Robert ^{[7
]}

Dabaja, Bouthaina ^{[8
]}

Duron, Ysabel

Forero, Andres ^{[9
]}

Gordon, Leo I. ^{[10
]}

Hernandez-Ilizaliturri, Francisco J. ^{[11
]}

Hochberg, Ephraim P. ^{[12
]}

Maloney, David G. ^{[13
]}

Mansur, David ^{[14
,15
]}

Mauch, Peter M. ^{[16
]}

Metzger, Monika ^{[17
]}

Moore, Joseph O. ^{[18
]}

Morgan, David ^{[19
]}

Moskowitz, Craig H. ^{[20
]}

Poppe, Matthew ^{[21
]}

Pro, Barbara ^{[22
]}

Winter, Jane N. ^{[10
]}

Yahalom, Joachim ^{[20
]}

Sundar, Hema

机构：

[1] Stanford Canc Inst, Stanford, CA USA

[2] UCSF Hellen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[3] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[4] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[6] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[7] City Hope Comprehens Canc Ctr, Duarte, CA USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[9] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA

[10] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[11] Roswell Pk Canc Inst, Buffalo, NY USA

[12] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[13] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA

[14] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[15] Washington Univ, Sch Med, St Louis, MO 63130 USA

[16] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[17] Univ Tennessee, Inst Canc, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA

[18] Duke Canc Inst, Durham, NC USA

[19] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[20] Mem Sloan Kettering Canc Ctr, New York, NY USA

[21] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[22] Fox Chase Canc Ctr, Philadelphia, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2012年 / 10卷 / 05期

关键词：

POSITRON-EMISSION-TOMOGRAPHY; STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMORADIOTHERAPY; FREE SURVIVAL; CYCLES; FDG-PET; CHEMOTHERAPY; RITUXIMAB; ABVD; DISEASE;

D O I：

10.6004/jnccn.2012.0061

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin Lymphoma (HL) include the clinical management of classical HL and lymphocyte-predominant HL (LPHL). Major changes have been incorporated into these guidelines since their inception. In the 2012 NCCN Guidelines for HL, PET scans are not recommended for interim restaging of patients with stage I to II favorable disease. After reevaluating the available evidence on the use of interim PET imaging, the panel recommends the use of diagnostic CT scan of involved sites for interim restaging after completion of chemotherapy for this group of patients. Maintenance rituximab for 2 years is included as an option for patients with stage IB to IIB or stage III to IV LPHL treated with rituximab alone in the first-line setting. Brentuximab vedotin is included as an option for patients with progressive disease or relapsed disease after second-line chemotherapy or high-dose therapy with autologous stem cell rescue. (JNCCN 2012;10:589-597)

引用

页码：589 / 597

页数：9

共 34 条

[1] Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease [J].